BR112021011684A2 - Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda - Google Patents

Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda

Info

Publication number
BR112021011684A2
BR112021011684A2 BR112021011684A BR112021011684A BR112021011684A2 BR 112021011684 A2 BR112021011684 A2 BR 112021011684A2 BR 112021011684 A BR112021011684 A BR 112021011684A BR 112021011684 A BR112021011684 A BR 112021011684A BR 112021011684 A2 BR112021011684 A2 BR 112021011684A2
Authority
BR
Brazil
Prior art keywords
bcl
inhibitor
treatment
venetoclax
myeloid leukemia
Prior art date
Application number
BR112021011684A
Other languages
English (en)
Inventor
Adrian Ochsenbein
Carsten Riether
De Haard Hans
Van Rompaey Luc
Nicolas Leupin
Samson Fung
Original Assignee
Argenx Bvba
Univ Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820582.3A external-priority patent/GB201820582D0/en
Priority claimed from GBGB1911007.1A external-priority patent/GB201911007D0/en
Priority claimed from GBGB1917701.3A external-priority patent/GB201917701D0/en
Application filed by Argenx Bvba, Univ Of Bern filed Critical Argenx Bvba
Publication of BR112021011684A2 publication Critical patent/BR112021011684A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda. a invenção se refere a terapias combinadas, particularmente terapias combinadas para o tratamento de malignidade mieloide. as terapias combinadas são particularmente úteis em métodos para o tratamento de leucemia mieloide aguda (lma). as terapias combinadas incluem um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a cd70 e um inibidor de bcl-2, de preferência venetoclax ou um sal farmaceuticamente aceitável do mesmo.
BR112021011684A 2018-12-18 2019-12-18 Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda BR112021011684A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1820582.3A GB201820582D0 (en) 2018-12-18 2018-12-18 CD70 combination therapy
GBGB1911007.1A GB201911007D0 (en) 2019-08-01 2019-08-01 CD70 combination therapy
GBGB1917701.3A GB201917701D0 (en) 2019-12-04 2019-12-04 CD70 Combination therapy
PCT/EP2019/085982 WO2020127503A1 (en) 2018-12-18 2019-12-18 Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BR112021011684A2 true BR112021011684A2 (pt) 2021-11-30

Family

ID=69104399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011684A BR112021011684A2 (pt) 2018-12-18 2019-12-18 Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda

Country Status (21)

Country Link
US (2) US11712468B2 (pt)
EP (2) EP4218761A1 (pt)
JP (1) JP7565921B2 (pt)
KR (1) KR20210106428A (pt)
CN (2) CN115920034A (pt)
AU (1) AU2019409936A1 (pt)
BR (1) BR112021011684A2 (pt)
CA (1) CA3117282A1 (pt)
DK (1) DK3890740T3 (pt)
ES (1) ES2941638T3 (pt)
FI (1) FI3890740T3 (pt)
HU (1) HUE061710T2 (pt)
IL (1) IL284015B2 (pt)
LT (1) LT3890740T (pt)
MX (1) MX2021007350A (pt)
PL (1) PL3890740T3 (pt)
PT (1) PT3890740T (pt)
SG (1) SG11202105197UA (pt)
TW (1) TWI848030B (pt)
UY (1) UY38511A (pt)
WO (1) WO2020127503A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN114727996A (zh) * 2019-06-20 2022-07-08 细胞基因公司 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN116249519A (zh) * 2020-08-29 2023-06-09 阿根思有限公司 治疗对bcl-2抑制剂具有降低的敏感性的患者的方法
AU2022316138A1 (en) * 2021-07-21 2023-11-30 Emory University Bak activators, pharmaceutical compositions, and uses in treating cancer
EP4396230A1 (en) * 2021-09-02 2024-07-10 F. Hoffmann-La Roche AG Antibodies for the treatment of aml
WO2023081721A1 (en) * 2021-11-03 2023-05-11 Board Of Regents, The University Of Texas System Methods relating to treatment of acute myeloid leukemia
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
CN114949230A (zh) * 2022-06-13 2022-08-30 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN117771177A (zh) * 2023-08-02 2024-03-29 首都医科大学附属北京儿童医院 维奈克拉自微乳化释药系统及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
WO2003039443A2 (en) 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
NZ533240A (en) 2001-11-27 2007-12-21 Oxford Glycosciences Uk Ltd Use of polypeptide for the treatment of epithelial-derived cancer
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
ES2347959T3 (es) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2005295595C1 (en) 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1872124A4 (en) 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
US20080280297A1 (en) 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
US8124738B2 (en) 2005-09-26 2012-02-28 Medarex, Inc. Human monoclonal antibodies to CD70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ612319A (en) 2006-06-12 2015-04-24 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
KR20090031931A (ko) 2006-07-24 2009-03-30 센다 겐세쓰 가부시키가이샤 금속선재의 스케일 제거방법과 장치
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
EA201000673A1 (ru) 2007-11-05 2011-04-29 Новартис Аг СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
PT2331136T (pt) 2008-09-26 2018-03-27 Oncomed Pharm Inc Agentes de ligação a frizzled e utilizações dos mesmos
WO2010117057A1 (ja) 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SI2464232T1 (sl) 2009-08-10 2016-03-31 Samumed, Llc. Indazolovi inhibitorji signalne poti WNT in njihova terapevtska uporaba
WO2011035433A1 (en) 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
ES2705015T3 (es) 2009-12-29 2019-03-21 Kyowa Hakko Kirin Co Ltd Anticuerpo anti-CD27
PT2581113T (pt) 2010-06-11 2018-07-04 Univ Kyushu Nat Univ Corp Anticorpo anti-tim-3
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
BR112014022812A2 (pt) 2012-03-15 2017-07-18 Janssen Biotech Inc anticorpos anti-cd27 humanos, métodos e usos
CA2867662A1 (en) 2012-03-21 2013-09-26 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
US9556144B2 (en) 2012-06-15 2017-01-31 Curegenix, Inc. Compound as WNT signaling inhibitor, composition, and use thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150315279A1 (en) 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6606505B2 (ja) 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
US20180244792A1 (en) 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
US10959993B2 (en) * 2015-11-03 2021-03-30 Genentech, Inc. Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
BR112018075176A2 (pt) 2016-06-09 2019-06-04 Dr Reddys Laboratories Ltd formas sólidas de venetoclax e processos para a preparação de venetoclax
WO2018009444A1 (en) 2016-07-06 2018-01-11 Concert Pharmaceuticals, Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
EP3535264A2 (en) 2016-08-12 2019-09-11 Mylan Laboratories, Limited Process for the preparation of venetoclax
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
CZ201769A3 (cs) 2017-02-06 2018-08-15 Zentiva, K.S. Pevné formy venetoclaxu
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療

Also Published As

Publication number Publication date
CA3117282A1 (en) 2020-06-25
CN115920034A (zh) 2023-04-07
HUE061710T2 (hu) 2023-08-28
ES2941638T3 (es) 2023-05-24
IL284015A (en) 2021-08-31
IL284015B1 (en) 2024-06-01
EP3890740B1 (en) 2023-03-01
SG11202105197UA (en) 2021-07-29
FI3890740T3 (fi) 2023-05-24
US20240033353A1 (en) 2024-02-01
KR20210106428A (ko) 2021-08-30
MX2021007350A (es) 2021-09-21
CN113226317B (zh) 2022-08-16
LT3890740T (lt) 2023-03-27
WO2020127503A1 (en) 2020-06-25
TWI848030B (zh) 2024-07-11
DK3890740T3 (da) 2023-05-08
US11712468B2 (en) 2023-08-01
UY38511A (es) 2020-07-31
CN113226317A (zh) 2021-08-06
IL284015B2 (en) 2024-10-01
JP7565921B2 (ja) 2024-10-11
PL3890740T3 (pl) 2023-07-24
EP4218761A1 (en) 2023-08-02
PT3890740T (pt) 2023-05-15
JP2022515077A (ja) 2022-02-17
TW202038958A (zh) 2020-11-01
AU2019409936A1 (en) 2021-05-27
EP3890740A1 (en) 2021-10-13
US20200222532A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1121813T1 (el) Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
BR112022008817A2 (pt) Terapias combinadas para tratamento de câncer
EP4085919A3 (en) Compositions and methods to treat cancer
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
MX2023013912A (es) Metodos para inhibir ras.
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.